|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Clevidipine#Warnings]] |
| {{Clevidipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| ===5.1 Need for Aseptic Technique===
| |
| | |
| Use aseptic technique and discard any unused product within 12 hours of stopper puncture [see Dosage and Administration (2.3)].
| |
| | |
| ===5.2 Hypotension and Reflex Tachycardia===
| |
| | |
| Cleviprex may produce systemic [[hypotension]] and reflex [[tachycardia]]. If either occurs, decrease the dose of Cleviprex. There is limited experience with short-duration therapy with beta-blockers as a treatment for Cleviprex-induced [[tachycardia]]. Beta-blocker use for this purpose is not recommended.
| |
| | |
| ===5.3 Lipid Intake===
| |
| | |
| Cleviprex contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism. For these patients, a reduction in the quantity of concurrently administered lipids may be necessary to compensate for the amount of lipid infused as part of the Cleviprex formulation.
| |
| | |
| ===5.4 Negative Inotropy===
| |
| | |
| Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor [[heart failure]] patients carefully.
| |
| | |
| ===5.5 Beta-Blocker Withdrawal===
| |
| | |
| Cleviprex is not a [[beta-blocker]], does not reduce heart rate, and gives no protection against the effects of abrupt [[beta-blocker]] withdrawal. [[Beta-blockers]] should be withdrawn only after a gradual reduction in dose.
| |
| | |
| ===5.6 Rebound Hypertension===
| |
| | |
| Patients who receive prolonged Cleviprex infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound [[hypertension]] for at least 8 hours after the infusion is stopped.
| |
| | |
| ===5.7 Pheochromocytoma===
| |
| | |
| There is no information to guide use of Cleviprex in treating [[hypertension]] associated with pheochromocytoma.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095081a0-1398-11dc-82e1-0002a5d5c51b | publisher = | date = | accessdate = 27 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Butyrates]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |